FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer

Clinical Cancer Research

Volumn 20, Issue 15, 2014, Pages 4107-4114

  Wang, Rui ^a,b   Wang, Lei ^a,b   Li, Yuan ^a,b   Hu, Haichuan ^a,b   Shen, Lei ^a,b   Shen, Xuxia ^a,b   Pan, Yunjian ^a,b   Ye, Ting ^a,b   Zhang, Yang ^a,b   Luo, Xiaoyang ^a,b   Zhang, Yiliang ^a,b   Pan, Bin ^a,b   Li, Bin ^a,b   Li, Hang ^a,b   Zhang, Jie ^a,b   Pao, William ^d   Ji, Hongbin ^c   Sun, Yihua ^a,b   Chen, Haiquan ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN RET; BAG4 PROTEIN, HUMAN; FGFR1 PROTEIN, HUMAN; FGFR2 PROTEIN, HUMAN; FGFR3 PROTEIN, HUMAN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; ONCOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TACC3 PROTEIN, HUMAN;

ADULT; AGED; ALK GENE; ARTICLE; BRAF GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EGFR GENE; FEMALE; FGFR1 GENE; FGFR2 GENE; FGFR3 GENE; GENE; GENE FUSION; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MIDDLE AGED; ONCOGENE K RAS; ONCOGENE NEU; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RET GENE; ROS1 GENE; SMOKING; TUMOR VOLUME; ADENOCARCINOMA; CANCER STAGING; CLASSIFICATION; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; LUNG TUMOR; METABOLISM; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE;

EID: 84905508021     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0284     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-94.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
5. Kohno T, Tsuta K, Tsuchihara K, Nakaoku T, Yoh K, Goto K. RET fusion gene: translation to personalized lung cancer therapy. Cancer Sci 2013;104:1396-400.
6. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70.
7. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
8. Li H, Pan Y, Li Y, Li C, Wang R, Hu H, et al. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer 2013;79:8-13.
9. Pan Y, Wang R, Ye T, Li C, Hu H, Yu Y, et al. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component. Chest 2014;145:473-9.
10. Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012;18:2443-51.
11. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling-A new therapeutic opportunity in cancer. Clin Cancer Res 2012;18:1855-62.
12. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012;337:1231-5.
13. Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J Clin Invest 2013;123:855-65.
14. Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, et al. FGFR2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2013;59:1427-34.
15. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013;3:636-47.
16. Sabnis AJ, Bivona TG. FGFR fusions in the driver's seat. Cancer Discov 2013;3:607-9.
17. Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian Patients. J Clin Oncol 2014;32:121-8.
18. Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012;30:4352-9.
19. Wang R, Pan Y, Li C, Hu H, Zhang Y, Li H, et al. The use of quantitative real-time reverse transcriptase PCR for 50 and 30 portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res 2012;18:4725-32.
20. Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer 2014;84:121-6.
21. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010;16:1561-71.
22. Yi ES, Boland JM, Maleszewski JJ, Roden AC, Oliveira AM, Aubry MC, et al. Correlation of IHC and FISH for ALK gene rearrangement in nonsmall cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011;6:459-65.